BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38691651)

  • 1. Lifileucel (Amtagvi): A cellular therapy for melanoma.
    Med Lett Drugs Ther; 2024 Apr; 66(1701):e77-e78. PubMed ID: 38691651
    [No Abstract]   [Full Text] [Related]  

  • 2. Opdualag for metastatic melanoma.
    Med Lett Drugs Ther; 2023 Jan; 65(1668):e19-e20. PubMed ID: 36651796
    [No Abstract]   [Full Text] [Related]  

  • 3. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
    Dummer R; Flaherty KT; Robert C; Arance A; B de Groot JW; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; Pietro AD; Cantey-Kiser J; Edwards M; Ascierto PA
    Future Oncol; 2023 May; 19(16):1091-1098. PubMed ID: 37309702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma.
    Li SN; Wan X; Peng LB; Li YM; Li JH
    BMC Health Serv Res; 2023 Jan; 23(1):49. PubMed ID: 36653848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
    Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma: An update on systemic therapies.
    Skudalski L; Waldman R; Kerr PE; Grant-Kels JM
    J Am Acad Dermatol; 2022 Mar; 86(3):515-524. PubMed ID: 34915056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
    Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
    Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the systemic treatment of metastatic melanoma.
    Yushak M; Kluger HM; Sznol M
    Oncology (Williston Park); 2013 May; 27(5):374-81. PubMed ID: 25184258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.
    Corrie P; Meyer N; Berardi R; Guidoboni M; Schlueter M; Kolovos S; Macabeo B; Trouiller JB; Laramée P
    Cancer Treat Rev; 2022 Nov; 110():102463. PubMed ID: 36099854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) - Lifileucel (Amtagvi).
    Parums DV
    Med Sci Monit; 2024 May; 30():e944927. PubMed ID: 38689550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
    Trojaniello C; Festino L; Vanella V; Ascierto PA
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lifileucel: the first cellular therapy approved for solid tumours.
    Julve M; Lythgoe MP; Larkin J; Furness AJS
    Trends Cancer; 2024 Jun; 10(6):475-477. PubMed ID: 38724322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].
    Di Guardo L
    Recenti Prog Med; 2022 Jun; 113(6):28e-30e. PubMed ID: 35758129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
    Graf NP; Koelblinger P; Galliker N; Conrad S; Barysch M; Mangana J; Dummer R; Cheng PF; Goldinger SM
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
    Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
    Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
    Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
    Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.